USA Multicenter Clinical Trial with Recombinant Human Erythropoietin (Amgen)

2015 ◽  
pp. 160-165 ◽  
Author(s):  
Joseph W. Eschbach ◽  
Michael R. Downing ◽  
Joan C. Egrie ◽  
Jeffery K. Browne ◽  
John W. Adamson
Keyword(s):  
Clinical Trial ◽  
Recombinant Human Erythropoietin ◽  
Multicenter Clinical Trial ◽  
Human Erythropoietin

scholarly journals Clinical effectiveness of 3 days preoperative treatment with recombinant human erythropoietin in total knee arthroplasty surgery: a clinical trial

QJM ◽  
2019 ◽  
Vol 113 (4) ◽  
pp. 245-252
Author(s):  
S -L Cao ◽  
Y Ren ◽  
Z Li ◽  
J Lin ◽  
X -S Weng ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Total Knee Arthroplasty ◽  
Blood Loss ◽  
Knee Arthroplasty ◽  
Recombinant Human Erythropoietin ◽  
Iron Supplement ◽  
Human Erythropoietin ◽  
Group A ◽  
Total Knee ◽  
Group B

Abstract Aims The purpose of study is to evaluate the effect and complication of preoperative short-term daily recombinant human erythropoietin (rhEPO) treatment for blood-saving in patients undergoing unilateral primary total knee arthroplasty (TKA). Methods This three-arm randomized clinical trial compared three different rhEPO-based treatment protocols for unilateral primary TKA. Group A: application of daily doses of rhEPO combined with iron supplement starting 3 days before surgery; Group B: application of daily doses of rhEPO combined with iron supplement starting the day of surgery; Group C: iron supplement alone. Perioperative hemoglobin (Hb) level gaps, total perioperative blood loss, reticulocyte levels and treatment-related complications were studied. Results A total of 102 patients were included (35, 35 and 32 patients in Groups A, B and C, respectively). Total blood loss (TBL) in Groups A, B and C was 490.84, 806.76 and 924.21 ml, respectively. Patients in Group A had a significant lower TBL than Groups B and C (A vs. B: P = 0.010; A vs. C: P < 0.001). There was no difference as for TBL between Groups B and C (P = 0.377). Group A patients had significant smaller Hb decline than Group C on the third and fifth postoperative day (P = 0.049, P = 0.037), as well as than Group B on the fifth postoperative day (P = 0.048). There was no difference as for Hb decline between Groups B and C. No difference was shown in levels of inflammatory biomarkers or blood-saving protocol-related complications among three groups. Conclusions Daily dose of rhEPO combined with iron supplement administered 3 days before TKA procedures could significantly decrease perioperative blood loss and improve postoperative Hb levels, without significantly elevating risks of complication, when compared with admission of rhEPO on the day of surgery and iron supplement alone. Preoperative daily rhEPO treatment could be a more effective blood-saving protocol in TKA procedures.

Sign in / Sign up

Export Citation Format

Share Document